MiR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

ABSTRACT:

Background

Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been extensively studied, however, not much is known about the involvement of microRNAs.

Methods

Differentially expressed microRNAs between cisplatin sensitive and resistant cancer cell line pairs were determined using microarrays. Mimics were used to study the role of microRNAs in drug sensitivity of ovarian cancer cell lines and patient derived tumor cells. Luciferase reporter constructs were used to establish regulation of target genes by microRNAs.

Results

MiR-634 downregulation was associated with cisplatin resistance. Overexpression of miR-634 affecte

SUBMITTER: van Jaarsveld MT 

PROVIDER: S-EPMC4650519 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature